as 08-22-2025 4:00pm EST
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Founded: | 2018 | Country: | Germany |
Employees: | N/A | City: | BERLIN |
Market Cap: | 444.7M | IPO Year: | 2021 |
Target Price: | $13.33 | AVG Volume (30 days): | 6.3M |
Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.69 | EPS Growth: | N/A |
52 Week Low/High: | $1.03 - $4.74 | Next Earning Date: | 08-14-2025 |
Revenue: | $2,309,000 | Revenue Growth: | 510.85% |
Revenue Growth (this year): | 423.05% | Revenue Growth (next year): | -86.43% |
ATAI Breaking Stock News: Dive into ATAI Ticker-Specific Updates for Smart Investing
Insider Monkey
a month ago
Zacks
a month ago
Insider Monkey
a month ago
Zacks
2 months ago
Insider Monkey
2 months ago
TipRanks
2 months ago
TipRanks
2 months ago
WSJ
2 months ago
The information presented on this page, "ATAI ATAI Life Sciences N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.